266 related articles for article (PubMed ID: 16964267)
21. Risk factors for acute graft-versus-host disease grades II-IV after reduced intensity conditioning allogeneic stem cell transplantation with unrelated donors: a single centre study.
Remberger M; Mattsson J; Hassan Z; Karlsson N; LeBlanc K; Omazic B; Okas M; Sairafi D; Ringdén O
Bone Marrow Transplant; 2008 Feb; 41(4):399-405. PubMed ID: 17982493
[TBL] [Abstract][Full Text] [Related]
22. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
[TBL] [Abstract][Full Text] [Related]
23. Risk assessment in haematopoietic stem cell transplantation: impact of donor-recipient sex combination in allogeneic transplantation.
Gahrton G
Best Pract Res Clin Haematol; 2007 Jun; 20(2):219-29. PubMed ID: 17448958
[TBL] [Abstract][Full Text] [Related]
24. Minor ABO-mismatches are risk factors for acute graft-versus-host disease in hematopoietic stem cell transplant patients.
Ludajic K; Balavarca Y; Bickeböller H; Rosenmayr A; Fischer GF; Faé I; Kalhs P; Pohlreich D; Kouba M; Dobrovolna M; Greinix HT
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1400-6. PubMed ID: 19822299
[TBL] [Abstract][Full Text] [Related]
25. [Effects and prognostic factors of HLA-matched sibling donor allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia].
Tong XZ; Li J; Tan EX; Zhang GC; Wu XY; Peng AH; Zheng D; Zou WY; Hong WD; Luo SK
Zhonghua Zhong Liu Za Zhi; 2006 Jul; 28(7):545-8. PubMed ID: 17147125
[TBL] [Abstract][Full Text] [Related]
26. Excellent outcome of allogeneic hematopoietic stem cell transplantation using a conditioning regimen with medium-dose VP-16, cyclophosphamide and total-body irradiation for adult patients with acute lymphoblastic leukemia.
Shigematsu A; Kondo T; Yamamoto S; Sugita J; Onozawa M; Kahata K; Endo T; Shiratori S; Ota S; Obara M; Wakasa K; Takahata M; Takeda Y; Tanaka J; Hashino S; Nishio M; Koike T; Asaka M; Imamura M
Biol Blood Marrow Transplant; 2008 May; 14(5):568-75. PubMed ID: 18410899
[TBL] [Abstract][Full Text] [Related]
27. Allogeneic stem cell transplantation in first complete remission enhances graft-versus-leukemia effect in adults with acute lymphoblastic leukemia: antileukemic activity of chronic graft-versus-host disease.
Lee S; Cho BS; Kim SY; Choi SM; Lee DG; Eom KS; Kim YJ; Kim HJ; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Shin WS; Kim CC
Biol Blood Marrow Transplant; 2007 Sep; 13(9):1083-94. PubMed ID: 17697971
[TBL] [Abstract][Full Text] [Related]
28. Prophylactic red blood cell exchange for prevention of severe immune hemolysis in minor ABO-mismatched allogeneic peripheral blood progenitor cell transplantation after reduced-intensity conditioning.
Worel N; Greinix HT; Supper V; Leitner G; Mitterbauer M; Rabitsch W; Fischer G; Rosenmayr A; Höcker P; Kalhs P
Transfusion; 2007 Aug; 47(8):1494-502. PubMed ID: 17655594
[TBL] [Abstract][Full Text] [Related]
29. Activating killer immunoglobulin-like receptor incompatibilities enhance graft-versus-host disease and affect survival after allogeneic hematopoietic stem cell transplantation.
Giebel S; Nowak I; Dziaczkowska J; Czerw T; Wojnar J; Krawczyk-Kulis M; Holowiecki J; Holowiecka-Goral A; Markiewicz M; Kopera M; Karolczyk A; Kyrcz-Krzemien S; Kusnierczyk P
Eur J Haematol; 2009 Oct; 83(4):343-56. PubMed ID: 19500138
[TBL] [Abstract][Full Text] [Related]
30. Immune hemolysis following ABO-mismatched stem cell or solid organ transplantation.
Yazer MH; Triulzi DJ
Curr Opin Hematol; 2007 Nov; 14(6):664-70. PubMed ID: 17898572
[TBL] [Abstract][Full Text] [Related]
31. A comparison between low intensity and reduced intensity conditioning in allogeneic hematopoietic stem cell transplantation for solid tumors.
Conrad R; Remberger M; Cederlund K; Ringdén O; Barkholt L
Haematologica; 2008 Feb; 93(2):265-72. PubMed ID: 18245651
[TBL] [Abstract][Full Text] [Related]
32. Major ABO blood group mismatch increases the risk for graft failure after unrelated donor hematopoietic stem cell transplantation.
Remberger M; Watz E; Ringdén O; Mattsson J; Shanwell A; Wikman A
Biol Blood Marrow Transplant; 2007 Jun; 13(6):675-82. PubMed ID: 17531777
[TBL] [Abstract][Full Text] [Related]
33. Role of antithymocyte globulin and granulocyte-colony stimulating factor-mobilized bone marrow in allogeneic transplantation for patients with hematologic malignancies.
Chen XH; Zhang C; Zhang X; Gao L; Gao L; Kong PY; Peng XG; Qi DG; Sun AH; Zeng DF; Liu H; Gong Y; Wang QY
Biol Blood Marrow Transplant; 2009 Feb; 15(2):266-73. PubMed ID: 19167687
[TBL] [Abstract][Full Text] [Related]
34. CCR5 deletion mutation and its association with the risk of developing acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
Bogunia-Kubik K; Duda D; Suchnicki K; Lange A
Haematologica; 2006 Dec; 91(12):1628-34. PubMed ID: 17145599
[TBL] [Abstract][Full Text] [Related]
35. Reduced intensity conditioning for allogeneic hematopoietic stem-cell transplant determines the kinetics of acute graft-versus-host disease.
Turner BE; Kambouris ME; Sinfield L; Lange J; Burns AM; Lourie R; Atkinson K; Hart DN; Munster DJ; Rice AM
Transplantation; 2008 Oct; 86(7):968-76. PubMed ID: 18852664
[TBL] [Abstract][Full Text] [Related]
36. Modified conditioning regimen busulfan-cyclophosphamide followed by allogeneic stem cell transplantation in patients with multiple myeloma.
Zhang XH; Huang XJ; Liu KY; Xu LP; Liu DH; Chen H; Chen YH; Wang JZ; Han W; Lu DP
Chin Med J (Engl); 2007 Mar; 120(6):463-8. PubMed ID: 17439737
[TBL] [Abstract][Full Text] [Related]
37. Allogeneic stem cell transplantation and donor lymphocyte infusions for chronic myelomonocytic leukemia.
Elliott MA; Tefferi A; Hogan WJ; Letendre L; Gastineau DA; Ansell SM; Dispenzieri A; Gertz MA; Hayman SR; Inwards DJ; Lacy MQ; Micallef IN; Porrata LF; Litzow MR
Bone Marrow Transplant; 2006 Jun; 37(11):1003-8. PubMed ID: 16604096
[TBL] [Abstract][Full Text] [Related]
38. Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma.
Kuruvilla J; Shepherd JD; Sutherland HJ; Nevill TJ; Nitta J; Le A; Forrest DL; Hogge DE; Lavoie JC; Nantel SH; Toze CL; Smith CA; Barnett MJ; Song KW
Biol Blood Marrow Transplant; 2007 Aug; 13(8):925-31. PubMed ID: 17640596
[TBL] [Abstract][Full Text] [Related]
39. Allogeneic peripheral blood hematopoietic stem cell transplantation: guidelines for red blood cell immuno-hematological assessment and transfusion practice.Société Française de Greffe de Moelle.
Lapierre V; Kuentz M; Tiberghien P
Bone Marrow Transplant; 2000 Mar; 25(5):507-12. PubMed ID: 10713627
[TBL] [Abstract][Full Text] [Related]
40. [Allogeneic hematopoietic stem cell transplantation in patients with chronic myeloid leukemia in the Czech Republic--a retrospective analysis of results in years 1988-2005].
Faber E; Koza V; Vítek A; Mayer J; Sedlácek P; Zák P; Zapletalová J; Benesová K; Krejcová H; Steinerová K; Maresová I; Cetkovský P
Vnitr Lek; 2006 Dec; 52(12):1172-80. PubMed ID: 17299910
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
